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Abstract
Several organotin derivatives of 1,2- and 1,7-dicarba-closo-dodecaboranes were
synthesized and characterized by lgsn M6ssbauer, 1H, 13C and 19Sn NMR spectroscopy.
Their antitumour activities in vitro against cancerous cell lines of human origin are reported.
Introduction
Boron derivatives present a potential interest in the anticancer therapy by neutron
capture provided these compounds exhibit a sufficiently selective affinity towards tumour
cells2. On the other hand, numerous tin derivatives exhibit promising in vitro antitumour
activities3 against as well as selectivities4 towards some human cancer cell lines. Thus, such
favourable properties can be expected from compounds combining boron and tin. In this
paper we report the synthesis, characterization and in vitro antitumour activities of such
compounds derived from 1,2- and 1,7-dicarba-closo-dodecaboranes5 (ortho- and meta-
carborane, respectively).
Synthesis
The ortho- and meta-carboran-9-yltin dichlorides were prepared according to [5]:
(C2BloHI-9)2Hg + SnC12 --> (C2B0HI-9)2SnCI2 + Hg.
The dicarboranyltin dichlorides were transformed into the corresponding oxides by reaction
with dilute aqueous sodium hydroxide:
(C2B 10H 1-9)2SNC12 + 2NaOH --> (C2B 10H11-9)2SnO + H20 + 2NaC1.
Both ortho- and meta-carboranyl tin oxides were reacted with 2,6-pyridine
dicarboxylic acid in a 1"1 molar ratio under elimination of water.
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The ortho-carboranyl tin oxide was likewise reacted with 2-L-pyrrolidone-5-carboxylic acid in
a 1:2 molar ratio:
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Antitumour Activities
O)
The in vitro antitumour activities observed for different human cancer cell lines are
shown in Table 1. In vivo screening results are given in table 2.
The high in vitro antitumour activity of 1 and 2 are noteworthy, especially for the MCF-7 line,
where they are comparable to those of doxombicin. Bis(metacarboranyl)tin dichloride exhibits
even higher activities in both MCF-7 and WiDr of the order of those of doxorubicin.
Compound 3 exhibits lower activities, though they remain superior to those of cisplatin.
Compound 2 is active in vivo against L1210 murine leukemia at doses of 7 and 10
mg/kg but toxic at 14 mg/kg (table 2). Noteworthy is that one mouse was cured at a dose of 7
mg/kg.
38M. Gielen, F. Kayser, O.B. Zhidkova, K Ts. Kampel, V.L Bredgadze, D. de Vos, Metal BasedDrugs
M. Biesemans, B. Mahieu and R. Willem
Table 1. In vitro antitumour activities of compounds 1 to 3 as well as of o-C2B 10H12 and
(m-C2BloHll-9)2SnC12 against two human cancer cell lines.
Compounds
o-C2BloH12
(m-C2B oH11-9)2SnCl2
1 (DMSO)
(EtOH)
2
Doxorubicin
Cisplatin
MCF-7 WiDr EVSAT IGROV M19MEL A498
36817 22456
5 31
10 102
14 197
11 45
60 410 48 3 30 110
8 20 6 28 5 5
800 1200 650 79 530 1200
Activities of 3 against other cell lines" A204: 49; IgR-37: 12; T24:32
Table 2. In vivo antitumour screening of compound 2 on groups of male DBA/2 mice
bearing leukaemia L1210. Doses applied, mean body weights, median survival times (MST),
T/C values and long-term survivors (LTS). The drug doses (mg/kg) were administered i.p. in
a single dose.
Treatment
7 mg/kg i.p.
10 mg/kg i.p.
14 mg/kg i.p.
Control
Mean body weight (g) MST T/C LTS
day da), 5 day 7. (day) %
25.6 23.4 25.3 14 140 1/6
25.4 21.1 21.1 14.5 145 0/6
24.6 20.7 20.4 5 50 0/6
25.1 25.9 27.4 10 100 0/9
Experimental Section
Instruments and Procedures
The M6ssbauer spectra were recorded as described previously6. The M6ssbauer parameters (IS
towards Ca119SNO3, QS, F) are given in mm/s.
The NMR spectra were recorded on a Bruker AC250 and/or a Broker AMX500 spectrometer.
On the AC250 instrument 1H, 13C and 119Sn spectra were recorded at 250.13, 62.90 and
93.28 MHz respectively. On the AMX500 spectrometer 1H and 13C spectra were recorded at
500.13 and 125.76 MHz respectively.
1H and 3C chemical shifts were referenced to the residual solvent peaks and converted to the
standard TMS scale. The ll9Sn chemical shift is given with respect to neat external
tetramethyltin (E(119Sn) = 37.290665 MHz)7,8. Chemical shifts are given in ppm and coupling
constants in Hz. Couplings involving the 1H, 117/119Sn and lib nuclei are given between
parenthesis, brackets and accolades respectively. Abbreviations used below: b = broad; s =
singlet; d = doublet; t = triplet; sep = septet; m = complex pattern.
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Characterization
(o-C2B0H-9)2SnCI" M6ssbauer" IS = 1.66; QS = 3.49; F = 0.87; Fe = 0.94.
(m-CzB0HI-9)zSnCI" M6ssbauer: IS = 1.66; QS = 3.50; F = 0.86; F = 0.86.
(o-CzB0H-9)SnO" A solution of 163.0 mg (4.07 mmol) of NaOH in 60 mL of H20 was
added dropwise to a solution of 807.6 mg (1.70 mmol) of (o-CzB0H -9)2SnC1 dissolved in
30 mL diethylether. After 2 hours, the precipitate formed was filtered off under vacuum and
washed with water and diethylether. Yield" 77 %. MOssbauer: IS 1.27; QS = 2.50; F =
1.10; F2 = 1.09.
(m-CB0H-9)zSnO: A similar procedure as for (o-CzB0H-9)zSnO was used. Yield: 86
%. M6ssbauer: IS = 1.39; QS = 3.27; F -0.98; 1-"2 = 0.94.
Compound 1" 371 mg (0.88 mmol) of (o-C9.B10H-9)SnO were added to a solution of 147
mg (0.88 mmol) of 2,6-pyridine dicarboxylic acid in 50 mL of ethanol/toluene (10/40). The
mixture was refluxed during 6 hours and the water/ethanol/toluene ternary azeotrope was
distilled off with a Dean-Stark funnel. Half the solvent was further evaporated. The white
crystals formed after one night were filtered off and recrystallised from ethanol. Yield: 65 %.
mp 325-328 C dec. M6ssbauer: IS = 1.56; QS = 3.82; F = 1.00; 1"2 -0.96. NMR (DMSO):
H NMR" CzH 2" 3.38 (bs); B0H9:1.1-3.5 (b); H3 = H5" 8.50 (d, 7.6); H4:8.69 (t, 7.6).
13C NMR: CH2" 59.8 [39]; C2 = C6: 145.4; C3 = C5" 126.5; C4: 146.7; C2’- C6’: 162.5.
l9Sn NMR: -166.3 1:2:3:4:3"2" 1 sep from couling with IB (I = 3/2), 1268 }.
Compound 2: A similar procedure as for compound 1 was used. Yield: 70%; mp > 350 C.
M6ssbauer: IS = 1.52; QS = 3.70; F = 0.91; F2 = 0.95. NMR (DMSO)" H NMR" C2H2:
3.49 (bs), B10H9" 1.0-3.5 (b); aromatic" H3 = H5" 8.50 (d, 7.6); H4:8.69 (t, 7.6). 13C NMR:
C2H2:59.7 [j(13Cll7/ll9Sn)" 40 Hz]; C2 = C6" 145.3; C3 = C5" 126.5; C4: 146.6; C2’=
C6’: 162.4. 19Sn NMR:-166.2 {sep, 1271}.
Compound 3" 300 mg (0.71 mmol) of (o-CB10Hll-9)SnO were added to a solution of 184
mg (1.42 mmol) of 2-L-pyrrolidone-5-carboxylic acid in 50 mL of ethanol/benzene (10/40).
The mixture was refluxed during 4 hours and the water/ethanol/toluene ternary azeotrope was
distilled off with a Dean-Stark funnel. The remaining solvent was evaporated under reduced
pressure. Recrystallisation from hexane/benzene yielded white needles" 79 %; mp 248-251 C.
M6ssbauer: IS = 1.62; QS = 3.83; F = 0.90; F2 = 0.95. NMR solvent" CDC13. H NMR"
C2H2:3.15 (bs), B10H9" 1.2-3.4 (b); NH: 6.13 (bs); H5" 4.29 (m); H3, H4:2.2 2.6 (m).
13C NMR: CH: 58.3 [j(13Clly/ll9Sn)" ca. 40 Hz, broad]; C5" 55.5; CH2: 25.2, 29.5; CO,
COOSn: 177.7, 179.5. 9Sn NMR:-61.0 {sep, 1230}.
Antitumour Tests
In Vitro Tests
The cytotoxicity of compounds 1 to 3, together with some reference compounds, was
determined in vitro against six well characterized human tumor cell lines by applying the
microculture sulforhodamine B test (SRB). The compounds were tested in quadruple at 10
concentrations varying with a factor 3, ranging from 3 to 59050 ng/ml.
Concentration response curves were determined and the IDa0 (drug concentration in ng/mL at
50% growth inhibition) values were calculated.
Prior to the experiments a mycoplasma test was carried out on all cell lines and found to be
negative. All cell lines, except EVSA-T, were maintained in a continuous logarithmic culture in
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RPMI medium with Hepes and Phenol red supplemented with 10% bovine calf serum (BCS),
penicillin 111 IU/ml, streptomycin 111 mg/ml, gentamycin 46 mg/ml and insulin 10.6 mg/ml.
EVSA-T was maintained in DMEM with 5% BCS and antibiotics as described. The cells were
mildly trypsinized for passage and for use in experiments.
RPMI, DMEM and SRB (sulforhodamine B) were obtained from Brunschwig (Amsterdam,
The Netherlands). BCS was obtained from Hyclone (Logan, Utah, USA), DMSO from Baker
(Deventer, The Netherlands), phosphate-buffered saline (PBS) from Boom (Meppel, The
Netherlands), insulin Neerlandicum from Organon (Oss, The Netherlands). Streptomycin,
penicillin, gentamycin and trypsin were obtained from Gibco (Breda, The Netherlands).
The test and reference compounds were dissolved to a concentration of 177147 ng/ml as
follows:
Organotin compounds: 1.0 to 2.2 % DMSO in full growth RPMI medium. Carboplatin: 10%
water in full growth RPMI medium
Cis-platin: 0.17% DMSO in full growth RPMI medium
No additional pretreatment, as ultra sonication, was needed for complete dissolution of all
compounds.
On day 1, 200 ml of trypsinized tumor cells (2000 cells/well) were plated in 96-wells
flatbottom microtiter plates (Costar, no. 3799, Badhoevedorp, The Netherlands). The plates
were preincubated for 24 hr at 37C, 5% CO2 to allow the cells to adhere.
On day 2, 100 ml of a solution with the highest drug concentration were added to the wells of
column 12 and from there diluted 3-fold to column 3 by serial transfer of 100 ml using an 8
channel micropipette. The final volume of column 3 was adjusted to 200 ml with PBS. Column
2 was used for the blank. PBS was added to column 1 to diminish interfering evaporation.
On day 7 the incubation was terminated by washing the plates twice with PBS. Subsequently
the cells were fixed with 10% trichloroacetic acid in Milli Q water (Millipore, Etten Leur, The
Netherlands) and placed at4C for one hour.
After five washings with tap water, the cells were stained for at least 15 min with 0.4% SRB,
dissolved in 1% acetic acid, and subsequently washed with 1% acetic acid to remove the
unbound stain. The plates were air dried and the bound protein stain was dissolved by using
150 ml 10 mmol/1 tris base. The absorbance was read at 540 nm using an automated microplate
reader (Titertec, Flow Laboratories Ltd., Irvine, Scotland).
In Vivo Tests on DBA/2 mice
Compound 2 was suspended in 2 % carboxymethylcellulose. The drug was administrated
intraperitoneally as a single injection in a volume of 10 mL/kg. On day 0, lxl05 L1210 cells
from a stock culture suspension were injected i.p. into male DBA/2 mice. After about 24 hours
treatment was started. The drug was administered by a single intraperitoneal injection to
groups of 6 mice. Each drug was tested at three dose levels. The highest doses were expected
to show toxicity. The untreated control group consisted of 9 mice. The average body weight of
the various groups was determined on the day of treatment (day 1), on day 5 and on day 7.
The survival time of the mice was recorded. The results are expressed as median survival time
(MST) of treated over control mice (T/C %).
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